PFE
PFE
$26.80
$-0.01 (-0.02%)
About
No description available for this stock.
Price History (Last 30 Days)
Latest News & Updates
Eli Lilly's weight-loss pill Foundayo received U.K. approval, marking Europe's f...
Eli Lilly's weight-loss pill Foundayo received U.K. approval, marking Europe's first GLP-1 oral medication authorization. The drug offers advantages over competitor Novo Nordisk's Wegovy with no food restrictions. The global obesity drug market is projected to grow from $66 billion in 2025 to $92-200 billion by 2027, presenting significant growth opportunities for multiple manufacturers.
The article compares AbbVie and CVS Health as healthcare investment options in 2...
The article compares AbbVie and CVS Health as healthcare investment options in 2026. AbbVie, a biopharmaceutical company with a $438B market cap, is recommended as the better choice due to its focused growth trajectory, strong drug pipeline (Skyrizi and Rinvoq), and attractive dividend yield. CVS Health, a diversified healthcare provider with a $122B market cap managing 37 million medical members, is acknowledged as a turnaround story showing stabilization but is considered less compelling than AbbVie's growth prospects.
Pfizer is developing berobenatide, a monthly injectable weight-loss drug that co...
Pfizer is developing berobenatide, a monthly injectable weight-loss drug that could compete with market leaders Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Phase 2b data shows 16% weight loss in 32 weeks with no plateau, positioning it as potentially competitive despite lower efficacy than rivals. The anti-obesity market is projected to reach $190 billion by 2035, offering significant opportunity, though Pfizer faces risks from patent cliffs, increased competition from companies like Amgen, and regulatory hurdles.
ResearchAndMarkets.com released a comprehensive report analyzing 1,350+ precisio...
ResearchAndMarkets.com released a comprehensive report analyzing 1,350+ precision medicine collaboration and licensing deals from 2019-2026. The report provides detailed benchmarking data on deal structures, financial terms, and contract provisions to support business development and strategy decisions in the precision medicine sector.
The global influenza vaccine market was valued at US$8.96 billion in 2024 and is...
The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, growing at a 7% CAGR. Market expansion is driven by rising public health awareness, an aging population, government immunization programs, and increased R&D investment. Quadrivalent and inactivated vaccines lead the market, while cell-based technologies and pediatric segments show fastest growth. Key players include GlaxoSmithKline, Pfizer, Sanofi, Moderna, and others.
Pfizer appears undervalued with a 6.8% dividend yield and low P/E ratio of 8.5x,...
Pfizer appears undervalued with a 6.8% dividend yield and low P/E ratio of 8.5x, but investors remain skeptical due to negative revenue growth over three years and upcoming patent cliffs, particularly for its blockbuster drug Eliquis. However, the company's deep pipeline in weight management and oncology, including promising candidates like MET-097i and PF-4404, could drive significant recovery if clinical trials succeed, making it potentially attractive for long-term income investors.
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The...
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The recognition highlights the company's achievements in advancing innovative cancer therapies, including the commercialization of olverembatinib and lisaftoclax, with multiple global Phase III clinical trials underway.
Pfizer's 6.8% dividend yield significantly exceeds market averages, raising conc...
Pfizer's 6.8% dividend yield significantly exceeds market averages, raising concerns about sustainability. However, management remains committed to maintaining and growing the dividend, as evidenced by Q1 2026 earnings presentations. The company generated sufficient operating cash flow to cover dividend payments and maintain a higher cash balance, supported by $11.3 billion in long-term investments. While Pfizer faces industry headwinds including patent expirations and delays in GLP-1 drug development, analysts suggest the company has the financial capacity to sustain its dividend through this challenging period.
The article recommends three dividend stocks suitable for long-term buy-and-hold...
The article recommends three dividend stocks suitable for long-term buy-and-hold investors: Pfizer, which is developing new blockbuster drugs and entering the obesity drug market; Coca-Cola, with 64 years of consecutive dividend increases and a resilient business model; and Brookfield Renewable, which offers recurring income from renewable energy assets with 5-9% annual dividend growth targets.
A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-...
A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.
